Select data courtesy of the U.S. National Library of Medicine.

© 2026 DeepDyve, Inc. All rights reserved.

This site is protected by VikingCloud's Trusted Commerce program
      Home

    Sarcoma

    Subject:
    Oncology
    Publisher:
    Hindawi — Wiley
    ISSN:
    1357-714X
    Scimago Journal Rank:
    45

    2024

    Volume 2024
    MarchFebruaryJanuary

    2023

    Volume 2023
    JulyJuneMayMarch

    2022

    Volume 2022
    DecemberOctoberAugustJuneMayAprilMarchJanuary

    2021

    Volume 2021
    OctoberSeptemberAugustJulyAprilMarchFebruaryJanuary

    2020

    Volume 2020
    DecemberOctoberSeptemberAugustJulyJuneMayAprilMarchFebruaryJanuary

    2019

    Volume 2019
    DecemberNovemberOctoberSeptemberAugustJulyJuneMayAprilMarchFebruaryJanuary

    2018

    Volume 2018
    AugustJulyJuneMayAprilMarchFebruaryJanuary

    2017

    Volume 2017
    Issue 2017 (Jan)

    2016

    Volume 2016
    Issue 2016 (Feb)
    Volume 8
    Issue 2-3 (Jul)
    Volume 7
    Issue 1 (Dec)
    Volume 6
    Issue 3 (Jul)Issue 1 (Dec)
    Volume 4
    Issue 4 (Mar)Issue 3 (Jul)
    Volume 3
    Issue 3-4 (Jul)
    Volume 1

    2015

    Volume 2015
    Issue 2015 (Apr)
    Volume 9
    Issue 1-2 (May)
    Volume 8
    Issue 4 (Jul)Issue 2-3 (Jul)
    Volume 7
    Issue 3-4 (Sep)Issue 2 (Nov)
    Volume 5
    Issue 4 (Apr)Issue 3 (Nov)
    Volume 4
    Issue 1-2 (Aug)

    2014

    Volume 2014
    MarchIssue 2014 (Dec)
    Volume 9
    Issue 3-4 (Sep)
    Volume 8
    Issue 4 (Sep)Issue 2-3 (Dec)Issue 1 (Sep)
    Volume 7
    Issue 2 (Nov)
    Volume 6
    Issue 4 (Oct)Issue 3 (Sep)Issue 1 (Sep)

    2013

    Volume 2013
    DecemberSeptemberJuneMayAprilMarchFebruaryIssue 2013 (Jun)

    2012

    Volume 2012
    DecemberAugustJuneMarchIssue 2012 (May)

    2011

    Volume 2011
    DecemberNovemberJulyJuneMayAprilMarchFebruaryJanuaryIssue 2011 (Mar)
    Volume 2010
    January

    2010

    Volume 2011
    DecemberOctoberSeptemberIssue 2011 (Dec)
    Volume 2010
    OctoberSeptemberMayMarchIssue 2010 (Mar)
    Volume 2009
    MarchFebruaryJanuary

    2009

    Volume 2009
    DecemberNovemberOctoberJuneMayAprilIssue 2009 (Mar)
    Volume 2008
    Issue 2008 (Feb)

    2008

    Volume 2008
    JuneMayMarchIssue 2008 (Aug)
    Volume 2007
    January

    2007

    Volume 2007
    DecemberJulyJuneMayIssue 2007 (Nov)
    Volume 2006
    Issue 2006 (Jan)

    2006

    Volume 2006
    DecemberSeptemberAugustIssue 2006 (Dec)

    2005

    Volume 9
    January

    2004

    Volume 8
    January

    2003

    Volume 7
    January

    2002

    Volume 6
    January

    2001

    Volume 5
    January

    2000

    Volume 4
    January

    1999

    Volume 3
    January

    1998

    Volume 2
    January

    1997

    Volume 1
    January
    journal article
    LitStream Collection
    ALDH1A1 Gene Expression and Cellular Copper Levels between Low and Highly Metastatic Osteosarcoma Provide a Case for Novel Repurposing with Disulfiram and Copper

    Mandell, Jonathan B.;Douglas, Nerone;Ukani, Vrutika;Beumer, Jan H.;Guo, Jianxia;Payne, John;Newman, Rebecca;Mancinelli, Luigi;Intini, Giuseppe;Anderson, Carolyn J.;Watters, Rebecca;Weiss, Kurt

    2022 Sarcoma

    doi: 10.1155/2022/7157507pmid: 35125923

    Aldehyde dehydrogenase 1A1 (ALDH) is a cancer stem cell marker highly expressed in metastatic cells. Disulfiram (Dis) is an FDA-approved antialcoholism drug that inhibits ALDH and has been studied as a candidate for drug repurposing in multiple neoplasia. Dis cytotoxicity in cancer cells has been shown to be copper-dependent, in part due to Dis&#x2019;s ability to function as a bivalent metal ion chelator of copper (Cu). The objectives of this research were to test <i>ALDH</i> expression levels and Cu concentrations in sarcoma patient tumors and human osteosarcoma (OS) cell lines with differing metastatic phenotypes. We also sought to evaluate Dis&#x2009;&#x2b;&#x2009;Cu combination therapy in human OS cells. Intracellular Cu was inversely proportional to the metastatic phenotype in human OS cell lines (SaOS2&#x2009;&#x3e;&#x2009;LM2&#x2009;&#x3e;&#x2009;LM7). Nonmetastatic human sarcoma tumors demonstrated increased Cu concentrations compared with metastatic tumors. qPCR demonstrated that <i>ALDH</i> expression was significantly increased in highly metastatic LM2 and LM7 human OS cell lines compared with low metastatic SaOS2. Tumor cells from sarcoma patients with metastatic disease displayed significantly increased <i>ALDH</i> expression compared with tumor cells from patients without metastatic disease. Serum Cu concentration in canine OS versus normal canine patients demonstrated similar trends. Dis demonstrated selective cytotoxicity compared with human multipotential stromal cells (MSCs): Dis-treated OS cells demonstrated increased apoptosis, whereas MSCs did not. CuCl<sub>2</sub> combined with Dis and low-dose doxorubicin resulted in a superior cytotoxic effect in both SaOS2 and LM7 cell lines. In summary, <i>ALDH</i> gene expression and Cu levels are altered between low and highly metastatic human OS cells, canine samples, and patient tumors. Our findings support the feasibility of a repurposed drug strategy for Dis and Cu in combination with low-dose anthracycline to specifically target metastatic OS cells.
    Browse All Journals

    Related Journals:

    Lancet Oncology, TheNature Reviews Clinical OncologySupportive Care in CancerEuropean Journal of Cancer CareCurrent Oncology ReportsJournal of OncologyCurrent OncologyTherapeutic Advances in Medical OncologyClinical Medicine Insights: OncologyCase Reports in Oncology
    Issue 3-4 (Jul)
    Volume 3
    Issue 3-4 (May)Issue 1 (Jul)
    Volume 2
    Issue 3-4 (Jul)Issue 2 (Jul)Issue 1 (Aug)
    Volume 1
    Issue 3-4 (Jul)Issue 2 (Jan)Issue 1 (Jan)
    Volume 5
    Issue 3 (Sep)Issue 2 (Oct)Issue 1 (Dec)
    Volume 4
    Issue 4 (Sep)Issue 3 (Sep)Issue 1-2 (Apr)
    Volume 3
    Issue 2 (Oct)Issue 1 (Oct)
    Volume 2
    Issue 3-4 (Oct)Issue 2 (Oct)Issue 1 (Nov)
    Volume 1
    Issue 3-4 (Oct)

    Showing 1 to 1 of 1 Articles

    Articles per page